NIKKEI 225
38,079.70 +117.90 (+0.31%) HANG SENG
16,385.87 +134.03 (+0.82%) CRUDE OIL
82.58 -0.15 (-0.18%) GOLD FUTURES
2,395.50 -2.50 (-0.10%) DOW
37,775.38 +22.07 (+0.06%) Bitcoin GBP
51,045.23 +1,733.62 (+3.52%)
Medigene AG (MDG1.F)
| Previous close | 1.8450 |
| Open | 1.8100 |
| Bid | 0.0000 x 60700 |
| Ask | 0.0000 x 58600 |
| Day's range | 1.8100 - 1.9550 |
| 52-week range | 1.3950 - 2.8500 |
| Volume | |
| Avg. volume | 3,083 |
| Market cap | 47.652M |
| Beta (5Y monthly) | 0.85 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.6600 |
| Earnings date | 26 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireMedigene to Present at Upcoming Scientific Conferences
Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, has been invited to present at the CHI's 8th Annual Immuno-Oncology Summit Europe from April 23-25, 2024, in London, UK, as well as at the 7th International Neoantigen Summit to be held in Amsterdam, Netherlands from April 29 - May 1, 2024. The presentations will be available on Medigene´s website after the c
- GlobeNewswire
Medigene Presents Favorable Safety Profile of TCR-T Cells with Costimulatory Switch Protein at AACR Annual Meeting 2024
Planegg/Martinsried, April 8, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today presents superior recombinant T cell receptor (rTCR) engineered T cell functionality as well as a favorable safety profile when rTCR-T cells are armored and enhanced with the PD1-41BB costimulatory switch protein (CSP) at the American Association for Cancer Research (
Globe NewswireMedigene AG Secures European Patent for its iM-TCR Technology
Planegg/Martinsried, April 4, 2024. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today announced that the Company has been issued a patent by the European Patent Office protecting its inducible Medigene T cell receptor (iM-TCR) technology, which contains a control mechanism to regulate efficacy and improve safety of its T cell receptor engineered T cell (TCR-T) therapie
